title: Fourier transform infrared imaging analysis of cancellous bone in alendronate- and raloxifene-treated osteopenic sheep.
abstract: Fourier transform infrared imaging spectroscopy (FTIRI)-assessed bone composition parameters (mineral content, collagen maturity, crystal size and perfection, and carbonate content) describe bone quality and correlate to bone fracture risk. The challenge with studying bone quality in patients treated with antiresorptive drugs such as bisphosphonates (e.g., alendronate) and selective estrogen receptor modulators (SERMs) (e.g. raloxifene) is being able to test bone mechanical performance and material properties pre- and posttreatment. The purpose of this study was to evaluate the FTIRI changes in a large animal model of osteoporosis (female sheep with dietary induced metabolic acidosis; MA). Previous studies have investigated the relationship between bone material properties and bone strength in humans and smaller animals and have shown that changes in compositional properties influence fracture risk. Here we characterize the MA model at 6 and 12 months, demonstrate the loss of bone and changes in compositional properties, and show that 6 months of treatment with both antiresorptives ameliorate the bone loss as assessed by bone mineral density and FTIRI. This preliminary data suggest that the MA sheep model allows investigation of whether drug treatments preserve bone properties that exist at the time of treatment or if they induce further beneficial changes.
authors: Grove School of Engineering, City College and the Graduate Center of the City University of New York, New York, NY, USA.
authors: Ericka F
authors: EF
authors: Calton
authors: Jennifer
authors: J
authors: Macleay
authors: Adele L
authors: AL
authors: Boskey
references: J Bone Miner Metab. 2004;22(6):561-8
references: 15490266
references: Swiss Med Wkly. 2001 Mar 10;131(9-10):127-32
references: 11416968
references: J Dent Res. 2010 Dec;89(12):1333-48
references: 20924069
references: J Bone Miner Res. 2001 Oct;16(10):1821-8
references: 11585346
references: Calcif Tissue Int. 1996 Jan;58(1):9-16
references: 8825233
references: Vet J. 2002 May;163(3):232-9
references: 12090765
references: Clin Orthop Relat Res. 2006 Feb;443:28-38
references: 16462423
references: Rev Endocr Metab Disord. 2001 Jan;2(1):117-27
references: 11704974
references: Am J Med. 2002 Mar;112(4):281-9
references: 11893367
references: Bone. 1995 Apr;16(4 Suppl):311S-315S
references: 7626320
references: Calcif Tissue Int. 2004 Nov;75(5):431-7
references: 15592799
references: Methods Mol Biol. 2008;455:293-303
references: 18463826
references: Bone. 1995 Apr;16(4 Suppl):277S-284S
references: 7626315
references: J Biomech. 1987;20(11-12):1055-61
references: 3323197
references: Bone. 2010 Mar;46(3):666-72
references: 19925895
references: J Bone Miner Res. 1995 Oct;10(10):1431-6
references: 8686497
references: Bone. 2002 Dec;31(6):675-84
references: 12531561
references: Osteoporos Int. 2009 May;20(5):793-800
references: 18769963
references: J Bone Miner Res. 2009 Sep;24(9):1565-71
references: 19419303
references: J Bone Miner Res. 2004 Aug;19(8):1250-8
references: 15231011
references: J Clin Endocrinol Metab. 2005 May;90(5):3115-21
references: 15713703
references: J Bone Miner Res. 2006 Oct;21(10):1581-90
references: 16995813
references: JAMA. 2002 Oct 16;288(15):1889-97
references: 12377088
references: Vib Spectrosc. 2005 Jul 29;38(1-2):107-114
references: 16691288
references: J Bone Miner Res. 1997 Nov;12(11):1936-43
references: 9383698